White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy
The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injections an Example
-
January 28, 2022
Downloads
Download Whitepaper
-
As new cancer therapies enter the market, it is paramount that treatments are safe, effective and provide high value to patients. At the same time, payers and policymakers not fully appreciate how the cost of administering cancer treatments impacts patient’s lives and may impose additional costs on health systems.
In a recent paper in Advances in Therapy, Dr. Jason Shafrin—a Senior Managing Director in FTI Consulting’s Center for Healthcare Economics and Policy—evaluates the case study of fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection compared to a comparable intravenous treatment. Dr. Shafrin finds that switching from an intravenous treatment to an injection creates benefits such as patients spending less time getting infusion treatment at the clinic. For health systems, injections reduce the staff time needed to supervise these infusions, and additional savings can be generated from reduced use of non-drug consumable costs (e.g., isopropyl alcohol wipes, opaque infusion giving sets, NaCl). In short, when treatments have similar safety and efficacy, health systems should look to minimize the burden of treatment for patients.
Originally published on January 5, 2022 in Springer Link. Jackisch, C., Manevy, F., Frank, S. et al. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example. Adv Ther (2022). https://doi.org/10.1007/s12325-021-01996-0 http://creativecommons.org/licenses/by-nc/4.0/
Published
January 28, 2022
Key Contacts
Senior Managing Director